



# Cannabis: The Good, The Bad and The Regulated

Saturday, June 16, 2018

9:00 AM-12:45 PM | Breakfast at 8:30 AM

**LOCATION:**

**The University Club of Washington, DC**  
1135 16th St NW, Washington, DC 20036



In recent years legislation has been passed governing the use, sale and prescription of cannabis and cannabidiol. The Washington Psychiatric Society is pleased to offer this workshop which will focus on the potential therapeutic benefits of cannabidiol for psychiatric disorders as well as the risks of cannabis use including psychosis and addiction in this still-evolving area of practice and research. Regulatory and legal issues related to prescribing medical marijuana in our region will also be discussed.

**WORKSHOP PRESENTERS**

**Britta Hahn, Ph.D.**



Britta Hahn obtained a Master’s degree in Neuroscience and a Ph.D. in Behavioral Pharmacology from the Institute of Psychiatry, King’s College London. She acquired a background in fMRI methods during her postdoctoral training at NIDA. Today, Dr. Hahn is an Associate Professor at the Maryland Psychiatric Research Center, University of Maryland School of Medicine. Her research revolves around cognition, schizophrenia, drug abuse, and effects of nicotine, with cannabidiol being a more recent interest.

**David Shurtleff, Ph.D.**




David Shurtleff is Acting Director of the National Center for Complementary and Integrative Health (NCCIH), performing a wide range of activities aimed toward directing, and implementing a program of research that builds a scientific evidence base about complementary and integrative health approaches that advances fundamental knowledge, and informs decision making by the public, by health care professionals, and by health policymakers. Dr. Shurtleff’s 23-year career at the National Institutes of Health (NIH) has focused on providing leadership and fostering an extensive research portfolio in the basic behavioral and neurosciences—cognitive studies, behavioral economics, decision theory, —and a broad spectrum of research that has contributed to cutting-edge research related to drug abuse, addiction, and complementary and integrative health care. He has received various honors and awards including several NIH Director’s Awards. One of these awards recognized his outstanding contributions to the 2014 President’s BRAIN Initiative.

**Susan Weiss, Ph.D.**



Susan Weiss is the Director, Division of Extramural Research at the National Institute on Drug Abuse (NIDA), which oversees NIDA’s extramural programs, research training, operations planning, and trans-NIH initiatives, such as the Adolescent Brain Cognitive Development (ABCD) study, and the BRAIN Initiative. Dr. Weiss also serves as a senior science advisor to the NIDA Director and scientific liaison to the NIH, HHS, and other Federal Agencies.

**Carla Williams, Esq.**



Carla M. Williams is a senior level Assistant General Counsel with the Department of Health’s Office of the General Counsel and has served in this capacity for fifteen years. Ms. Williams has been the principal legal advisor to the District’s Medical Marijuana Program since its inception in 2010. Additionally, she also currently serves as counsel to the District of Columbia Boards of Pharmacy and Dentistry, as well as to the Department of Health’s Pharmaceutical Control Division. Ms. Williams graduated from the University of Maryland School of Law with Honor, and an emphasis in health law.

**Arian Gibson**



Arian Gibson has served in the role of Program Manager of the Division of Medical Marijuana and Integrative Therapy with the Department of Health for the past 9 months. He graduated with a BS in Environmental Science and biology from North Carolina Central University. He is currently studying Food Safety Regulation at The John Hopkins University for a MS. Mr. Gibson previously was the Program Manager for the Food Safety Division at the Department of Health. Mr. Gibson has over 20 years of experience in the public health field.

**AGENDA**

- 8:30 AM–9:00 AM Registration and Breakfast
- 9:00 AM–9:10 AM Welcome & introductions – *CME Committee*
- 9:10 AM–9:40 AM **The Potential of Cannabidiol as a Treatment for Cannabis Addiction and Psychosis** – *Britta Hahn, Ph.D.*
- 9:40 AM–9:50 AM Q&A
- 9:50 AM–10:20 AM **Cannabis Addiction, Risk of Psychosis and Other Adverse Effects** – *Susan Weiss, Ph.D.*
- 10:20 AM–10:30 AM Q&A
- 10:30 AM–10:40 AM Break
- 10:40 AM–11:10 PM **Therapeutic Use of Cannabis in Pain, Anxiety Disorders Including PTSD** – *David Shurtleff, Ph.D.*
- 11:10 AM–11:20 PM Q&A
- 11:20 AM–11:30 AM Break
- 11:30 AM–12:00 PM **Recommending Medical Marijuana: Program Operations and Legal Considerations** – *Carla Williams, Esq. and Arian Gibson*
- 12:00 PM–12:10 PM Q&A
- 12:10 PM–12:40 PM **Panel: Drs. Hahn, Weiss, Shurtleff, Ms. Williams, Esq. and Mr. Gibson**
- 12:40 PM–12:45 PM Wrap up

**REGISTRATION FEES**

	ADVANCE	AFTER 6/2
Medical Student/Resident/Fellow	\$30	\$40
WPS Member	\$85	\$110
Non-Physician/Other	\$145	\$170
Non-Member Physician	\$145	\$170

Please email [admin@dcpsych.org](mailto:admin@dcpsych.org) with any questions.

**CLICK HERE FOR REGISTRATION**

THANK YOU TO OUR PLATINUM SPONSOR



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and Washington Psychiatric Society (WPS). The APA is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.